6533b7defe1ef96bd1276573
RESEARCH PRODUCT
false
T WölfelLi LiJochen GreinerT F E BarthHartmut DöhnerMark RinghofferMichael Schmittsubject
Cancer Researchbusiness.industryCD34Myeloid leukemiamedicine.diseaseLeukemiachemistry.chemical_compoundImmune systemOncologychemistryAntigenImmunologyHyaluronic acidGeneticsCancer researchMedicineStem cellbusinessReceptordescription
RHAMM/CD168 was defined as a LAA using the approach of serological screening of expression libraries (SEREX), eliciting IgG responses in 42% of patients with AML, but not in healthy volunteers (HV) or patients with autoimmune diseases. mRNA for RHAMM was demonstrated by qRT-PCR to be expressed in leukemic blasts of more than 80% of the AML patients, but not in PBMN or CD34+ stem cells of healthy volunteers. Among normal tissues, only testis, placenta and thymus showed significant mRNA expression for the antigen, therefore sharing the expression profile of some other SEREX antigens.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2004-01-01 | Cancer Cell International |